Date/Time: Tuesday, July 23, 2019 - 4:00 PM to 6:00 PM
Log in to Add to My Schedule
EUNCL, the European Nanomedicine Characterisation Laboratory, fosters innovation in nanomedicine by providing since 2015 access to state of the art full characterisation of nanomaterials intended for medical applications, developed by public labs, spin –offs and innovative SMEs. EUNCL provides for free a comprehensive set of characterisation tests (physical, chemical, in vitro and in vivo biological properties) allowing researchers and SMEs to better understand or predict the clinical in vivo effects of their medical nanomaterials. The knowledge base developed by EUNCL helps the European Medicines Agency (EMA) or other relevant agencies to adapt the current regulation and approval process to Nanomedicine products. EUNCL also serves as a European knowledge base for researchers and industry ensuring that European knowledge is documented in Europe for the benefit of the European economy, healthcare systems and patients.
To fulfill its mission EUNCL aims to achieve 4 major objectives:
- To qualify a comprehensive portfolio of medical nanoparticles preclinical characterisation assays (more than 40 assays) within an efficient collaborative environment over the first year of EUNCL
- To provide preclinical characterisation of medical nanoparticles to researchers, developers and inventors from academia and industry developing Med-NPs by opening trans-national access (TNA).
- To constantly refine and upgrade the assay portfolio and processes of EUNCL.
- To disseminate the EUNCL findings to the nanomedicine stakeholders in order to strengthen the innovation potential in that field.
EUNCL panellists will introduce during the session the lessons learned over 4 years of operation with 30+ nanomedicine products, on methods development and standardisation, physical-chemical, in vitro and vivo characterisations.